top of page

FDA approves Teva's Igalmi for at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder

Writer: nuaxia
nuaxia
1 hour ago
2 min read

The FDA has expanded the authorised use of Teva's Igalmi sublingual film to at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar disorder, introducing a new outpatient treatment setting.


Teva announced on 16 November 2026 that the US Food and Drug Administration had approved Igalmi (dexmedetomidine) sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar I or II disorder in adults, extending the medicine's use beyond healthcare-supervised administration.


The approval was supported by the Phase III SERENITY At-Home safety and tolerability study, which evaluated 1160 treated agitation episodes in 102 patients, and follows Teva's October 2026 acquisition of the Igalmi assets from BioXcel Therapeutics; the decision concerns a new setting of care for an existing medicine, with commercialisation plans not yet announced.

Field

Content

Article Type

Approvals

Company

Teva

Product Brand Name

Igalmi

Active Ingredient

Dexmedetomidine

Dosage Form

Sublingual film

Regulatory Authority

US Food and Drug Administration

Approval Date

16 November 2026

Regulatory Decision

Expanded authorised setting of care

Geographic Scope

United States

New Treatment Setting

At-home administration

Previous Treatment Setting

Healthcare-supervised administration

Therapeutic Area

Psychiatry

Treatment Purpose

Acute agitation

Approved Population

Adults with agitation associated with specified psychiatric disorders

Indication One

Schizophrenia

Indication Two

Schizoaffective disorder

Indication Three

Bipolar I disorder

Indication Four

Bipolar II disorder

Supporting Clinical Trial

SERENITY At-Home

Clinical Trial Phase

Phase III

Trial Focus

Safety and tolerability of at-home treatment

Treated Agitation Episodes

1160

Study Participants

102

Original Asset Developer

BioXcel Therapeutics

Asset Acquirer

Teva

Asset Acquisition Date

October 2026

First FDA-Approved At-Home Treatment Claim

First at-home treatment for agitation associated with the specified conditions according to supplied summary

New Active Ingredient Approval

No

Commercialisation Plans

Not yet announced according to supplied summary

What Happened

The FDA authorised Igalmi for at-home management of acute agitation in adults with specified psychiatric conditions.

Why It Matters

The approval introduces an additional treatment setting that may reduce reliance on healthcare facilities for eligible agitation episodes.

Clinical Significance

The supporting study evaluated safety and tolerability across more than one thousand treated agitation episodes.

Regulatory Significance

Expands an existing medicine's approved use from supervised administration to the home setting.

Strategic Significance

Creates a new potential commercial opportunity for Teva following its acquisition of the Igalmi assets.

Regulatory Clarification

This is a setting-of-care expansion rather than approval of a new molecular entity.

Key Takeaway

Igalmi is now FDA-approved for at-home treatment of acute agitation associated with specified psychiatric disorders in adults.

What to Watch

Prescribing guidance, patient and caregiver training, commercial launch plans, real-world safety and treatment adoption.

Primary Source

Teva

Primary Source URL

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--FDA-Approves-IGALMI-as-First-At-Home-Acute-Treatment-for-Agitation-Associated-with-Schizophrenia-Schizoaffective-Disorder-or-Bipolar-I-or-II-Disorder-in-Adults/default.aspx

Relevant Date

16 November 2026


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page